Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncor floats French subsidiary:

This article was originally published in Clinica

Executive Summary

US company Oncor has floated its French subsidiary, Appligene Oncor, on the French stock exchange, le Nouveau Marche. Around 336,000 shares, or 21% of Appligene, were sold at a price of Fr 163 ($31.70) each. Gross proceeds of around $11 million will be used to continue expansion of Oncor's European operations, including selected acquisitions of technology and business units. Based in Gaithersburg, Maryland, Oncor manufactures gene-based test systems to detect cancer.

You may also be interested in...



Oxford/AstraZeneca Vaccine Shows 70% Efficacy As Company Prepares Approval Filings

Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.

EBITDA Margin Of 33% Not Sustainable, Krka Underlines

Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.

Pandemic Spotlights Tensions Between Profit And Philanthropy

The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.

Topics

UsernamePublicRestriction

Register

LL1134786

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel